CN115243762A - 抗tmprss6抗体及其用途 - Google Patents

抗tmprss6抗体及其用途 Download PDF

Info

Publication number
CN115243762A
CN115243762A CN202180007339.2A CN202180007339A CN115243762A CN 115243762 A CN115243762 A CN 115243762A CN 202180007339 A CN202180007339 A CN 202180007339A CN 115243762 A CN115243762 A CN 115243762A
Authority
CN
China
Prior art keywords
seq
ser
tmprss6
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180007339.2A
Other languages
English (en)
Chinese (zh)
Inventor
杜欣
陈布新
王玉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxwell Usa Biotherapy Co ltd
Original Assignee
Maxwell Usa Biotherapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxwell Usa Biotherapy Co ltd filed Critical Maxwell Usa Biotherapy Co ltd
Publication of CN115243762A publication Critical patent/CN115243762A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180007339.2A 2020-04-07 2021-04-05 抗tmprss6抗体及其用途 Pending CN115243762A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063006695P 2020-04-07 2020-04-07
US63/006,695 2020-04-07
US202163158265P 2021-03-08 2021-03-08
US63/158,265 2021-03-08
PCT/US2021/025775 WO2021207072A1 (en) 2020-04-07 2021-04-05 Anti-tmprss6 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN115243762A true CN115243762A (zh) 2022-10-25

Family

ID=75888147

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180007339.2A Pending CN115243762A (zh) 2020-04-07 2021-04-05 抗tmprss6抗体及其用途

Country Status (9)

Country Link
US (3) US12215170B2 (OSRAM)
EP (1) EP4126220A1 (OSRAM)
JP (1) JP7813234B2 (OSRAM)
KR (1) KR20230007368A (OSRAM)
CN (1) CN115243762A (OSRAM)
AU (1) AU2021251087A1 (OSRAM)
CA (1) CA3174339A1 (OSRAM)
TW (1) TW202204422A (OSRAM)
WO (1) WO2021207072A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230295345A1 (en) * 2020-04-07 2023-09-21 Mabwell Therapeutics, Inc. Anti-tmprss6 antibodies and uses thereof
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
AU2022274888A1 (en) * 2021-05-11 2023-12-07 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
CN120752046A (zh) * 2022-11-25 2025-10-03 迈威(美国)生物治疗有限公司 抗tmprss6抗体及其用途
EP4688867A2 (en) * 2023-04-04 2026-02-11 Disc Medicine, Inc. Anti-tmprss6 antibodies and uses thereof
AU2024243972A1 (en) * 2023-04-06 2025-10-23 Memorial Hospital For Cancer And Allied Diseases Il-10 receptor antibodies and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013070786A1 (en) * 2011-11-07 2013-05-16 Isis Pharmaceuticals, Inc. Modulation of tmprss6 expression
WO2014099391A1 (en) * 2012-12-17 2014-06-26 Eli Lilly And Company Bmp-6 antibodies
JP2018529756A (ja) * 2015-07-31 2018-10-11 メディミューン リミテッド ヘプシジン媒介性障害を治療するための方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US20050054027A1 (en) 2003-09-09 2005-03-10 Irm Llc Modulators of transmembrane protease serine 6
GB0614201D0 (en) 2006-07-18 2006-08-23 Univ Cardiff Matriptase-2
AR065083A1 (es) * 2007-02-02 2009-05-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
DE112014005975T5 (de) 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
WO2016071701A1 (en) * 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
CA3162880A1 (en) 2019-11-29 2021-06-03 Kymab Limited Treatment for physiological iron overload
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
BR112023022284A2 (pt) 2021-04-26 2023-12-26 Alnylam Pharmaceuticals Inc Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
AU2022265493A1 (en) 2021-04-27 2023-09-21 Silence Therapeutics Gmbh Sirna targeting tmprss6 for the treatment of myeloproliferative disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013070786A1 (en) * 2011-11-07 2013-05-16 Isis Pharmaceuticals, Inc. Modulation of tmprss6 expression
WO2014099391A1 (en) * 2012-12-17 2014-06-26 Eli Lilly And Company Bmp-6 antibodies
JP2018529756A (ja) * 2015-07-31 2018-10-11 メディミューン リミテッド ヘプシジン媒介性障害を治療するための方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WAKE MATTHEW等: "Generation and Characterisation of KY1066, a Fully Human Antibody Targeting the Enzymatic Activity of Matriptase-2 forthe Treatment of Iron Overload in Beta Thalassemia", BLOOD.AMERICAN SOCIETY OF HEMATOLOGY, vol. 134, no. 13, 13 November 2019 (2019-11-13), pages 3532 *
张亨山, 赵金垣, 张振龙, 王春荣, 刘采云, 陈晓龙, 刘宏, 马东星, 张琰萍, 史德林, 倪道明: "抗金属硫蛋白的单克隆抗体", 中华劳动卫生职业病杂志, no. 06, 20 December 1997 (1997-12-20), pages 11 - 15 *

Also Published As

Publication number Publication date
EP4126220A1 (en) 2023-02-08
JP2023520969A (ja) 2023-05-23
JP7813234B2 (ja) 2026-02-12
CA3174339A1 (en) 2021-10-14
AU2021251087A1 (en) 2022-12-01
WO2021207072A1 (en) 2021-10-14
US20230203196A1 (en) 2023-06-29
US20230348623A1 (en) 2023-11-02
US12215170B2 (en) 2025-02-04
KR20230007368A (ko) 2023-01-12
TW202204422A (zh) 2022-02-01
US20250304719A1 (en) 2025-10-02
US11866513B2 (en) 2024-01-09

Similar Documents

Publication Publication Date Title
JP7813234B2 (ja) 抗ｔｍｐｒｓｓ６抗体及びその用途
JP6923658B2 (ja) 抗ｃｄ４７抗体およびその使用
CN108136001B (zh) 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
JP6367233B2 (ja) 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用
RU2571224C2 (ru) Гуманизированные антитела против axl
EP2997042B1 (en) Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
KR20190133160A (ko) 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
KR102513989B1 (ko) 간 질환을 치료하거나 예방하는 방법
KR102933484B1 (ko) 항-il-27 항체 및 그의 용도
WO2020168555A1 (zh) Cd3抗原结合片段及其应用
TW200938630A (en) Humanized antibodies specific for von willebrand factor
RU2744909C2 (ru) Способ лечения или предотвращения инсульта
MX2014010060A (es) Anticuerpos contra la endotelina 1 grande (et - 1 grande) y sus usos.
CN110381988A (zh) 使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
KR20250160366A (ko) 항-il-27 항체 및 이의 용도
CN115380049A (zh) 对生理性铁过载的治疗
US20230295345A1 (en) Anti-tmprss6 antibodies and uses thereof
HK40079278A (en) Anti-tmprss6 antibodies and uses thereof
JP2024534083A (ja) 補体代替経路阻害剤を用いて鎌状赤血球症又はベータサラセミアを治療する方法
CA3048799A1 (en) Compounds binding human cd160 and uses thereof
US20250136718A1 (en) Anti-tmprss6 antibodies and uses thereof
CN118078985A (zh) 抗tmprss6抗体及其用途
HK40104812A (zh) 抗tmprss6抗体及其用途
KR20250128393A (ko) 항-tmprss6 항체 및 그의 용도
RU2790023C2 (ru) Способы лечения заболевания с применением ингибиторов костного морфогенетического белка 6 (вмр6)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079278

Country of ref document: HK